Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:43:35.834Z.
Consensus retrieved: 2026-10-06T17:46:37.560Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:43:35.834Z.
Quote observation: 2026-10-06T18:40:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 585a3fa8f386aad11ebe73a449868628a330eb5daed7f9bf25448ccf0238b64c
Forward PE Ratio (N/A) = Dated Quote Price ($2.49) / Consensus Forward EPS ($-0.70)
FORWARD PE RATIO
N/A
Veru Inc.
Market Cap
$39.94M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Veru Inc. (VERU) | $39.94M | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.40M | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | N/A |
| Nephros, Inc. (NEPH)vs › | $39.08M | 22.98 |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.47M | N/A |
| Precipio, Inc. (PRPO)vs › | $41.98M | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.88M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.75M | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $43.56M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $2.49, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-0.70 | $-0.70 – $-0.70 | 1 | n/m |
| 2028-09-30 | $-0.69 | $-0.89 – $-0.49 | 2 | n/m |
| 2029-09-30 | $-0.63 | $-0.63 – $-0.63 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
